- Home
- NDMO vs PHAR Comparison
NDMO vs PHAR Comparison
Compare NDMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- PHAR
- Stock Information
- Founded
- NDMO 2019
- PHAR 1988
- Country
- NDMO United States
- PHAR Netherlands
- Employees
- NDMO N/A
- PHAR N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- PHAR Health Care
- Exchange
- NDMO Nasdaq
- PHAR Nasdaq
- Market Cap
- NDMO 596.2M
- PHAR 627.5M
- IPO Year
- NDMO N/A
- PHAR N/A
- Fundamental
- Price
- NDMO $10.24
- PHAR $9.38
- Analyst Decision
- NDMO
- PHAR Strong Buy
- Analyst Count
- NDMO 0
- PHAR 3
- Target Price
- NDMO N/A
- PHAR $27.00
- AVG Volume (30 Days)
- NDMO 218.6K
- PHAR 5.8K
- Earning Date
- NDMO 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- NDMO 6.75%
- PHAR N/A
- EPS Growth
- NDMO N/A
- PHAR N/A
- EPS
- NDMO N/A
- PHAR N/A
- Revenue
- NDMO N/A
- PHAR $285,745,000.00
- Revenue This Year
- NDMO N/A
- PHAR $20.08
- Revenue Next Year
- NDMO N/A
- PHAR $9.22
- P/E Ratio
- NDMO N/A
- PHAR N/A
- Revenue Growth
- NDMO N/A
- PHAR 30.64
- 52 Week Low
- NDMO $8.99
- PHAR $6.65
- 52 Week High
- NDMO $11.24
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- NDMO 48.78
- PHAR 49.69
- Support Level
- NDMO $10.08
- PHAR $9.14
- Resistance Level
- NDMO $10.25
- PHAR $10.15
- Average True Range (ATR)
- NDMO 0.12
- PHAR 0.57
- MACD
- NDMO 0.04
- PHAR -0.12
- Stochastic Oscillator
- NDMO 95.35
- PHAR 12.44
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.